MoonLake Immunotherapeutics (MLTX) – Analysts’ Weekly Ratings Changes

MoonLake Immunotherapeutics (NASDAQ: MLTX) has recently received a number of price target changes and ratings updates:

• 1/20/2026 – MoonLake Immunotherapeutics was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 1/14/2026 – MoonLake Immunotherapeutics was downgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “sell” rating. They now have a $10.00 price target on the stock, up previously from $8.00.
• 1/9/2026 – MoonLake Immunotherapeutics was given a new $24.00 price target on by analysts at UBS Group AG.
• 1/9/2026 – MoonLake Immunotherapeutics was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $24.00 price target on the stock.
• 1/9/2026 – MoonLake Immunotherapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock, up previously from $26.00.
• 1/8/2026 – MoonLake Immunotherapeutics had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $45.00 price target on the stock.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, CEO Da Silva Jorge Santos sold 70,000 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the completion of the sale, the chief executive officer directly owned 2,878,577 shares in the company, valued at $41,710,580.73. This represents a 2.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kristian Reich sold 72,908 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total value of $1,052,062.44. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 402,908 shares of company stock worth $5,987,162. Corporate insiders own 12.05% of the company’s stock.

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.